Novo Nordisk Files for Regulatory Approval of Faster-Acting Insulin Aspart in the US for the Treatment of Type 1 and 2 Diabetes
Bagsværd, Denmark, 9 December 2015 - Novo Nordisk today announced the submission of the New Drug Application (NDA) for faster-acting insulin aspart to the US Food and Drug Administration (FDA). Faster-acting insulin aspart is a mealtime insulin for... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 9, 2015 Category: Pharmaceuticals Source Type: clinical trials

Keryx Biopharmaceuticals Announces Zerenex (ferric citrate) Meets Primary and All Key Secondary Endpoints in Phase 3 Long-Term Study as a Treatment for Hyperphosphatemia in End-Stage Renal Disease Patients on Dialysis
Zerenex Significantly Increases Iron Storage Parameters and Decreases Need for Intravenous Iron and Erythropoiesis-Stimulating Agents Versus Active Control U.S. and European New Drug Application Submissions Anticipated in Second Quarter... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 28, 2013 Category: Pharmaceuticals Source Type: clinical trials